Cantor Fitzgerald Analysts Give Heron Therapeutics (HRTX) a $31.00 Price Target
Heron Therapeutics (NASDAQ:HRTX) has been assigned a $31.00 price target by analysts at Cantor Fitzgerald in a research note issued on Monday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 44.86% from the company’s current price.
The analysts wrote, “Late Friday, Jan. 12, Tesaro (Not Covered) announced that it had modified the Warnings section of the package insert for Varubi to include post-marketing reports of anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions, some requiring hospitalization.””
Other equities research analysts also recently issued reports about the stock. Mizuho reiterated a “buy” rating and set a $28.00 price target on shares of Heron Therapeutics in a report on Tuesday, November 7th. Cowen reiterated a “buy” rating and set a $40.00 price target on shares of Heron Therapeutics in a report on Monday, November 6th. Oppenheimer started coverage on shares of Heron Therapeutics in a report on Monday, October 30th. They set a “buy” rating and a $27.00 price target for the company. Noble Financial restated a “buy” rating and issued a $24.00 target price on shares of Heron Therapeutics in a report on Friday, October 6th. Finally, Zacks Investment Research upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 target price for the company in a report on Wednesday, November 22nd. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Heron Therapeutics currently has an average rating of “Buy” and an average target price of $28.82.
Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.77) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.10. The business had revenue of $8.57 million during the quarter, compared to the consensus estimate of $8.12 million. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. analysts expect that Heron Therapeutics will post -3.38 EPS for the current fiscal year.
In related news, VP Kimberly Manhard sold 7,584 shares of the business’s stock in a transaction that occurred on Wednesday, January 10th. The shares were sold at an average price of $20.00, for a total value of $151,680.00. Following the completion of the sale, the vice president now directly owns 7,584 shares in the company, valued at $151,680. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 19.93% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Private Asset Management Inc. grew its stake in Heron Therapeutics by 190.6% during the fourth quarter. Private Asset Management Inc. now owns 86,975 shares of the biotechnology company’s stock worth $1,574,000 after buying an additional 57,050 shares during the period. Rubric Capital Management LP grew its stake in Heron Therapeutics by 11.8% during the third quarter. Rubric Capital Management LP now owns 1,900,000 shares of the biotechnology company’s stock worth $30,685,000 after buying an additional 200,000 shares during the period. Perceptive Advisors LLC purchased a new stake in Heron Therapeutics during the third quarter worth approximately $5,329,000. Janus Henderson Group PLC grew its stake in Heron Therapeutics by 2.2% during the third quarter. Janus Henderson Group PLC now owns 5,767,495 shares of the biotechnology company’s stock worth $93,145,000 after buying an additional 126,039 shares during the period. Finally, Jane Street Group LLC purchased a new stake in Heron Therapeutics during the third quarter worth approximately $223,000. Institutional investors own 98.21% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/01/15/cantor-fitzgerald-reaffirms-buy-rating-for-heron-therapeutics-hrtx.html.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.